CClinicalTrials.gg
CompletedNCT05862727PASSUpdated Feb 4, 2026

Preschool Attention and Sleep Support (PASS)

An interventional study of Telehealth Intervention in ADHD and Psychiatric Health, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 3 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
3 Years to 5 Years
Sex
All
01

Study summary

This study will be investigating two telehealth interventions for preschoolers with ADHD. The study is divided into two Aims. During Aim 1, caregivers of preschoolers with attention concerns, pediatric behavioral health professionals, and pediatric primary care providers will take part in two virtual focus groups to provide their perspective on ways to improve the telehealth intervention being evaluated.

Read the detailed description

During Aim 2, caregivers of preschool children with ADHD symptoms will be randomly assigned to participate in one of two 9-week telehealth interventions. Both interventions will teach evidence-based skills and provide practice opportunities to manage their children's ADHD-related behaviors. Caregivers and their children will also attend three study visits (one before the intervention, and two following the intervention) where they will be asked to complete questionnaires and assessments related to the child's ADHD symptoms, psychiatric health, and sleep habits. Following each study visit, participating children will be asked to wear an ActiGraph device on their nondominant wrist for 24 hours/day for a 7-day period. During this time, the caregivers will be asked to complete an electronic daily diary about their child's sleep.

02

Conditions studied

  • ADHD
  • Psychiatric Health

Keywords

  • Psychiatric Health
  • Children
  • Preschool
  • ADHD
  • Telehealth Intervention
03

In context

Attention Deficit Disorder with Hyperactivity

1,514 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 255 are open to participants now.

This study's enrollment of 46 is below the median of 72 across 1,207 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.

Browse Attention Deficit Disorder with Hyperactivity studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • child must be ages 3-5 years at intake
  • child with score of 30 on the Child Sleep Habits Survey-Short Form and a caregiver rating of child's sleep problems as moderate/severe
  • child with ≥80th percentile on the clinician-rated ADHD-RS based on age and sex norms, with at least 4 symptoms in the clinically significant range (scores of 2-3) in either the inattention or hyperactive/impulsive domains
  • parent/caregiver must have ability to speak, read, and write in English
  • parent/caregiver must have access to a device with internet and/or smartphone to access telehealth visits
  • parent/caregiver must have ability to follow written and verbal instructions
  • parent/caregiver must have ability and willingness to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • child with suspected obstructive sleep apnea or restless legs syndrome (via screening questionnaires)
  • child with current use of stimulant medication, other psychotropics, or medications for sleep (prescription or over-the-counter, including melatonin)
  • child with caregiver report of psychiatric disorder other than ADHD requiring treatment (medication and/or therapy), Autism Spectrum Disorder, or intellectual disability
  • parent/caregiver is currently participating in another parent training intervention or have previously participated in another parent training intervention in the past 6 months.
  • Severe and/or uncontrolled medical condition (e.g., pulmonary and neurological conditions such as cystic fibrosis and seizure disorder) that would interfere with sleep and/or study participation according to the study team
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    PASS Arm1

    Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, such as establishing daytime and bedtime routines, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.

    Behavioral: Telehealth Intervention

  • Active comparator
    PASS Arm2

    Caregivers will receive sessions of evidence-based behavioral parent training which focuses on improving behaviors, including in home and public settings, through enhancement of positive parenting skills, including modifying antecedents, applying/withdrawing positive attention as a consequence, and shaping behavior using salient rewards.

    Behavioral: Telehealth Intervention

Interventions

  • BehavioralTelehealth Intervention

    Telehealth intervention that teaches caregivers evidence-based skills and provides practice opportunities to manage their children's ADHD-related behaviors according to their assigned intervention.

06

What researchers measure

Primary outcomes

  1. Change in clinician-rated ADHD-RS

    A clinician-rated, 18-item assessment with a 4-point Likert scale ranging from Rarely or never to Very Often. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  2. Change in caregiver-reported sleep habits as measured by the Short-Form Child Sleep Habits Questionnaire (SF-CSHQ).

    A 23-item questionnaire with a 3-point Likert scale ranging from Rarely to Usually. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  3. Change in Sleep Regularity Index (SRI)

    A measure of sleep regularity collected continuously over 7 days via Actigraphy. The SRI is calculated as the proportion of pairs of time points 24 hours apart that have matching sleep/wake status

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

Secondary outcomes

  1. Change in psychosocial function as measured by Impairment Rating Scale

    A clinician rated, 8-item assessment with a 7-point Likert scale ranging from No problem; definitely does not need treatment/special services to Extreme Problem; definitely needs treatment/special services. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  2. Change in parenting stress as measured by the Parenting Stress Scale

    An 18-item questionnaire with a 5-point Likert Scale ranging from Strongly disagree to Strongly Agree. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  3. Change in comorbid symptoms as measured by Child Behavioral Checklist for Ages 1½ to 5(CBCL)

    A widely-used 99-item parent report questionnaire with a 3-point Likert Scale ranging from Not True to Very True or Often True. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  4. Change in sleep midpoint, TST (minutes from sleep start to sleep end), SOL (minutes to first sleep epoch), WASO (minutes awake between sleep start and sleep end), and SE (TST/time in bed).

    As measured via actigraphy collected continuously over 7 days.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  5. Change in parenting style as measured by the Alabama Parenting Questionnaire

    A 33-item questionnaire with a 5-point Likert Scale ranging from Never to Always.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

  6. Change in severity of behavior problems in the home setting as measured by the Home Situations Questionnaires.

    A 16-item questionnaire with a 9-point Likert Scale. Lower scores indicate better outcomes.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

Other outcomes

  1. Treatment Fidelity

    The percentage of content and practices of the PASS protocol that were delivered (yes/no) across providers as determined by rater's assessment of recorded sessions.

    Time frame: During the 9-week treatment

  2. Feasibility of Recruitment

    The percentage of enrolled participants who attend a screening visit.

    Time frame: Baseline

  3. Feasibility of Randomization

    The percent of randomized participants who meet study eligibility after attending the screening visit.

    Time frame: Baseline

  4. Integrity of the control condition as measured by the PASS Fidelity Checklist.

    The incidence of administration of core PASS elements in each session of the control group determined by rater.

    Time frame: During the 9-week treatment

  5. Integrity of the control condition as measured by the Integrity of the Blind questionnaire.

    Asking all blinded informant (parents, assessors) to guess whether the child was in the control or experimental group and to state their confidence in this guess on a 1 to 10 scale. Higher scores indicate higher confidence in guess.

    Time frame: immediately post-treatment

  6. Index of treatment engagement as measured by attendance.

    Average number PASS groups sessions attended by participants.

    Time frame: During the 9-week treatment

  7. Adherence to between-session practice.

    Assessed via a therapist-completed item assessing the degree to which the caregiver was adherent overall with homework immediately after each session on a scale of 1 (not at all) to 5 (extremely strong).

    Time frame: During the 9-week treatment

  8. Retention

    Measured by the number of families who complete post-treatment and follow-up assessments.

    Time frame: Immediately post-treatment, 3 months post-treatment

  9. Acceptability as measured by the Satisfaction with Therapy and Therapist Scale (STTS-R).

    A 13-item questionnaire with a 5-point Likert Scale ranging from Strongly Disagree (1) to Strongly Agree (5). Higher scores indicate better outcomes.

    Time frame: Immediately post-treatment

  10. The Client Credibility Questionnaire

    4 item questionnaire to determine how logical and successful the treatment is; if they would recommend the intervention to others; and how much symptoms improved.

    Time frame: Immediately post-treatment

  11. Parenting Sense of Competence Scale

    A 17-item questionnaire with a 6-point Likert Scale ranging from Strongly Disagree (1) to Strongly Agree (6). A higher score indicates a higher parenting sense of competency.

    Time frame: Baseline, immediately post-treatment, 3 months post-treatment

07

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
08

References and documents

Publications

  • Davis NO, Eichner B, Gibson MJ, Lunsford-Avery JR. Preschool attention and sleep support (PASS): protocol for a pilot feasibility randomized clinical trial. Front Sleep. 2026 Feb 6;4:1662221. doi: 10.3389/frsle.2025.1662221. eCollection 2025. PubMed 41728023 ↗

Study documents

  • Informed consent form · Sep 4, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial (including data dictionaries) will be available for this study after deidentification.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05862727
Lead sponsor
Duke University
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
May 17, 2023
Start date
Jul 24, 2023
Primary completion
Jan 30, 2026
Completion
Jan 30, 2026
Last update
Feb 4, 2026

Study contacts

Jessica Lunsford-Avery, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion